Precipio, Inc. — Filing identity and reporting period
Issuer mismatch: The supplied filing is Transgenomic, Inc.’s Form 10-K, not a filing under the name Precipio, Inc. It reports the fiscal year ended December 31, 2015, with 2014 comparative results; it is not a quarterly report for 2015 Q4.
Transgenomic’s continuing business was primarily an Omaha laboratory-services operation supporting pharmaceutical and biotechnology clinical trials. Its strategy centered on commercializing MX-ICP, a mutation-detection technology, through services, products, licenses, and partnerships. The company classified its Genetic Assays and Platforms business and Patient Testing business as discontinued operations.
Financial performance and position
| Metric | 2015 | 2014 |
|---|---|---|
| Continuing-operations revenue | $1.653 million | $1.240 million |
| Gross profit (loss) | $(0.287) million; margin (17%) | $(0.935) million; margin (75%) |
| Operating expenses | $8.908 million | $9.634 million |
| Operating loss, continuing operations | $(9.195) million | $(10.569) million |
| Net loss, continuing operations | $(10.138) million | $(10.779) million |
| Net loss, discontinued operations | $(22.816) million | $(3.163) million |
| Consolidated net loss | $(32.954) million | $(13.942) million |
| Operating cash flow, continuing operations | $(7.854) million | $(6.169) million |
- Continuing revenue grew 33%, principally from contract laboratory services. Gross loss narrowed as revenue increased and laboratory costs declined. Lower stock compensation and patent costs contributed to reduced operating expenses.
- At December 31, 2015, cash was $0.444 million; current assets were $3.282 million and current liabilities $16.981 million, leaving negative working capital of $13.699 million. Total debt was $7.596 million, all classified as current after covenant noncompliance. Debt included a $3.025 million revolving line, a $4.000 million term loan, and $0.571 million of convertible notes.
- Consolidated operating cash use was $12.378 million, including $7.854 million from continuing operations and $4.524 million from discontinued operations. Total investing cash flow was positive $1.787 million, including $2.210 million from discontinued-operations asset sales. Financing provided $8.991 million; cash declined by $1.165 million during the year.
- Discontinued operations generated $18.584 million of revenue, down from $25.843 million, and recorded a $22.816 million net loss. The reported loss included $13.942 million of long-lived-asset impairment charges.
Material changes, outlook, and risks
- Portfolio shift: The company sold its Columns Business for approximately $2.1 million, recording a $1.5 million gain. It sold the remaining Genetic Assays and Platforms assets and related facilities for approximately $0.3 million and recorded a $1.7 million loss. It also began pursuing divestiture of Patient Testing; testing services were suspended in March 2016 while alternatives were evaluated.
- Going concern: Recurring losses, cash use, and negative working capital led management and the auditor to state that substantial doubt existed about the company’s ability to continue as a going concern. Management’s plan relied on improving operating results and collections, monetizing underused assets, and potentially obtaining further financing. The filing says the company might be unable to meet obligations through December 31, 2016 if those measures failed.
- Financing and debt: The company raised approximately $6.2 million net in a February 2015 public offering and approximately $3.0 million gross in a July 2015 private placement. In January 2016, it raised approximately $2.2 million gross (about $2.0 million net, as described in the filing) through preferred stock and warrants. A January 2016 loan amendment waived specified defaults, reduced revenue covenants, and extended the loan maturity to November 1, 2017. At year-end 2015, however, the company was not in compliance with loan financial covenants; lenders held a security interest in company assets and could accelerate debt if defaults were not cured or waived.
- Dilution and listing risk: In January 2016, existing preferred stock and accrued dividends converted into 6,780,179 common shares. The filing also reported substantial outstanding options, warrants, and conversion rights. Nasdaq notified the company in February 2016 that it did not meet the $1.00 minimum bid-price requirement, with an initial compliance deadline of August 22, 2016.
- Commercial outlook: Management’s stated objective was to expand MX-ICP clinical use and secure licensing and strategic partners; it expected near-term revenue from services, products, and licensing, with licensing envisioned as the larger longer-term source. The filing provides no specific revenue, earnings, or cash-flow guidance. Product adoption, partner execution, reimbursement, competition, regulatory requirements, collection performance, and access to capital remain material uncertainties.
- Other unusual items: The company recorded $6.2 million of continuing-operations long-lived-asset impairment charges in the third quarter and $6.9 million of goodwill impairment in discontinued operations in the fourth quarter. The 2015 discontinued-operations sale result was a net loss of $0.224 million, reflecting the gain and loss on the separate transactions.
- The independent auditor issued an unqualified opinion on the financial statements but included a going-concern emphasis. Management reported that previously identified material weaknesses in revenue recognition and receivables allowances were remediated during 2015; the auditor did not provide an internal-control attestation.
Most important facts for investors to verify
- Confirm the issuer: the provided 10-K identifies Transgenomic, Inc.; it does not identify Precipio, Inc.
- Review subsequent cash, collections, asset-sale proceeds, and operating cash burn against the company’s going-concern plan and near-term obligations.
- Check the status of loan defaults or waivers, covenant compliance, debt repayment terms, and any lender remedies or collateral claims.
- Assess the terms and potential dilution or cash obligations associated with the 2016 preferred financing, warrants, and preferred-stock conversion.
- Verify the status and financial impact of the Patient Testing suspension or divestiture and the completed Genetic Assays and Platforms sales.
- Evaluate whether MX-ICP products and partnerships are generating commercial adoption and recurring revenue, rather than relying on stated market potential.
- Check Nasdaq continued-listing compliance and any subsequent changes to the company’s capital structure or share count.